Paul A. Wagner's most recent trade in Forte Biosciences Inc was a trade of 1,250 Restricted Stock Units done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Forte Biosciences Inc | Wagner Paul A. | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 1,250 | 7,500 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Wagner A. Paul | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 1,250 | 81,038 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.44 per share. | 01 Jul 2025 | 98 | 80,940 | - | 12.4 | 1,219 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,250 | 8,750 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,250 | 79,806 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.44 per share. | 01 Apr 2025 | 18 | 79,788 | - | 7.4 | 134 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 920,000 | 920,000 | - | - | Stock Option (right to buy) | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 1,250 | 78,720 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 1,250 | 10,000 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.71 per share. | 01 Jan 2025 | 164 | 78,556 | - | 22.7 | 3,724 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 1,250 | 77,568 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 1,250 | 11,250 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.16 per share. | 01 Oct 2024 | 98 | 77,470 | - | 5.2 | 506 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 31,250 | 1,910,424 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 31,250 | 312,500 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.55 per share. | 01 Jul 2024 | 2,453 | 1,907,971 | - | 0.5 | 1,339 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 31,250 | 1,881,627 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 31,250 | 343,750 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.71 per share. | 01 Apr 2024 | 2,453 | 1,879,174 | - | 0.7 | 1,735 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 1,100,000 | 1,100,000 | - | - | Stock Option (right to buy) | |
| Forte Biosciences Inc | A. Wagner Paul | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 31,250 | 375,000 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Wagner Paul A. | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 31,250 | 1,854,486 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Wagner A. Paul | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.82 per share. | 01 Jan 2024 | 4,109 | 1,850,377 | - | 0.8 | 3,376 | Common Stock |
| Forte Biosciences Inc | Wagner A. Paul | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.75 per share. | 18 Dec 2023 | 10,000 | 1,823,236 | - | 0.8 | 7,525 | Common Stock |
| Forte Biosciences Inc | Wagner A. Paul | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.70 per share. | 13 Dec 2023 | 10,520 | 1,803,236 | - | 0.7 | 7,351 | Common Stock |
| Forte Biosciences Inc | Paul Wagner A. | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.72 per share. | 13 Dec 2023 | 10,000 | 1,813,236 | - | 0.7 | 7,200 | Common Stock |
| Forte Biosciences Inc | A. Paul Wagner | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.65 per share. | 11 Dec 2023 | 25,000 | 1,787,940 | - | 0.6 | 16,188 | Common Stock |
| Forte Biosciences Inc | Wagner Paul A. | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.65 per share. | 11 Dec 2023 | 4,776 | 1,792,716 | - | 0.6 | 3,088 | Common Stock |
| Forte Biosciences Inc | Wagner Paul A. | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.58 per share. | 07 Dec 2023 | 36,203 | 1,747,940 | - | 0.6 | 21,168 | Common Stock |
| Forte Biosciences Inc | A. Wagner Paul | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.62 per share. | 07 Dec 2023 | 15,000 | 1,762,940 | - | 0.6 | 9,300 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 1.01 per share. | 31 Jul 2023 | 247,524 | 1,675,574 | - | 1.0 | 249,999 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2023 | 31,250 | 437,500 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2023 | 31,250 | 1,430,503 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.04 per share. | 01 Jul 2023 | 2,453 | 1,428,050 | - | 1.0 | 2,551 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2023 | 31,250 | 1,410,299 | - | 0 | Common Stock | |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2023 | 31,250 | 468,750 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.01 per share. | 01 Apr 2023 | 11,046 | 1,399,253 | - | 1.0 | 11,156 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2023 | 500,000 | 500,000 | - | - | Restricted Stock Units | |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 1.03 per share. | 15 Dec 2022 | 55,976 | 1,335,025 | - | 1.0 | 57,672 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 1.07 per share. | 15 Dec 2022 | 44,024 | 1,379,049 | - | 1.1 | 47,000 | Common Stock |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 May 2022 | 40,000 | 135,000 | - | - | Stock Option (right to buy) | |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2022 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Forte Biosciences Inc | Paul A. Wagner | Director, See Remarks, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2021 | 175,000 | 175,000 | - | - | Stock Option (right to buy) |